Oncaspar 3750 IU Injection

Oncaspar 3750 IU Injection

Prescription requiredRx Required

Salt Composition: Pegaspargase

Expiry Date: 01/2028

Special offer

Enquire

Inclusive of all taxes

▼

1 Injection

About The Product

lymphoblastic leukemia

Oncaspar 3750 IU Injection belongs to the category of anticancer medicines. This medicine is primarily used to treat acute lymphoblastic leukemia and Hodgkin's disease in blood cancer patients. The growth of cancer cells is uncontrollable and abnormal in the human body. It is difficult to diagnose cancer in the early stages. When diagnosed in advanced stages, only the symptoms of the disease can be reduced.

Overview

Oncaspar 3750 IU Injection is a formulation containing pegaspargase, an anti-cancer enzyme used in combination therapy to treat acute lymphoblastic leukemia (ALL). Pegraspargase works by reducing the amount of asparagine in the body, thereby limiting leukemia cell growth and survival.

Most common side effects of Oncaspar 3750 IU Injection include nausea, vomiting, stomach pain, allergic reactions, increased sugar levels, and liver enzyme irregularities. It should be given under the supervision of a doctor with regular monitoring for liver issues, pancreatitis, blood clotting, and bleeding.

Quick Product Facts

Item

Detail

Generic name

Pegaspargase (pegylated L-asparaginase)

Strength and form

3,750 IU per 5 mL (750 IU/mL), clear, colorless, preservative-free solution in a single-dose vial

Strength and form

750 U/mL powder for solution for injection or infusion; each vial holds 3,750 U.

Marketer

Servier Laboratories Limited / Servier Pharmaceuticals

Route

Intramuscular or intravenous

Dose limit

No more often than every 14 days

Storage

2 to 8 degrees Celsius in the original carton, protected from light. Do not shake or freeze. Unopened vials may stay at 15 to 25 degrees C for up to 48 hours.

Diluted solution

Use at once, or keep at 2 to 8 degrees Celsius for up to 48 hours, protected from sunlight.

Prescription status

Prescription medicine for hospital use

Price control

The price of the Oncaspar 3750 IU injection depends on the location, the manufacturer, and its availability.

Price

The price of the Oncaspar 3750 IU injection is not fixed; it depends on several factors

Uses and Indications

The Oncaspar 3750 IU Injection has mainly two uses:

  • First-line treatment of acute lymphoblastic leukemia (ALL) in children and adults

  • Treatment of ALL in children and adults who are hypersensitive to native forms of L-asparaginase.

Oncaspar 3750 IU injection is always part of a combination, and your oncologist's protocol sets the schedule.

How It Works

Some leukemia cells cannot make enough of the amino acid asparagine and depend on the blood supply for it. Oncaspar 3750 IU injection breaks asparagine down into aspartic acid and ammonia, which starves those cells.

The PEG coating keeps the enzyme active for much longer than the native enzyme. In one study of newly diagnosed high-risk patients, blood asparagine stayed below the assay limit for at least 11 days after a single 2,500 IU/m² dose.

The half-life is about 5.3 to 5.8 days. That is why doses are spaced two weeks or more apart.

Clinical Evidence

According to clinical trials, Oncaspar 3750 IU Injection (pegaspargase) produces positive results in the treatment of acute lymphoblastic leukemia (ALL) when it is included in combination chemotherapy. The randomized clinical trial conducted on 118 children revealed that the Oncaspar 3750 IU Injection was able to deplete asparagine levels similar in efficiency to that of native E. coli L-asparaginase. This means that it can be suggested for treatment of ALL patients who are hypersensitive to the native asparaginase.

Study

Setting

Key result

CCG-1962

118 children aged 1 to 9 with standard-risk ALL: Oncaspar vs native E. coli asparaginase in combination therapy

Similar asparagine depletion (to 1 micromolar or less) at all time points. Three-year event-free survival is similar, about 80%. The study was not designed to compare survival.

DFCI 11-001

119 children and adolescents with new ALL or lymphoblastic lymphoma: Oncaspar 2,500 IU/m² with the DFCI backbone

Safety study. Median 16 doses over a median of 8 months.

Four open-label studies

42 patients with multiply relapsed leukemia (39 with ALL) and earlier allergy to asparaginase

Re-induction response 50%: 36% complete and 14% partial remission.

The evidence for people allergic to the native enzyme is small: 42 patients in four open-label studies. Even in that group, about one in three (32%) still reacted to the Oncaspar 3750 IU injection, so they are watched closely. Oncaspar 3750 IU injection is not a stand-alone treatment, and the trials were mostly in children, so adult figures are limited.

Side Effects

The most common grade 3 or 4 reactions (over 5%) are low albumin, raised liver enzymes, febrile neutropenia, high triglycerides, high blood sugar, raised bilirubin, pancreatitis, abnormal clotting tests, clots, allergy, sepsis, and infections. Most patients also receive other chemotherapy, so not every effect is due to the Oncaspar 3750 IU injection.

Grade 3 or higher effect (DFCI 11-001, 119 patients)

Number

Per cent

Raised liver enzymes (transaminases)

79

66%

Febrile neutropenia

48

40%

High triglycerides

36

30%

Low albumin

33

28%

Raised bilirubin

30

25%

High blood sugar

29

24%

Pancreatitis (lab or clinical)

29

24%

Abnormal clotting tests

25

21%

Clots (embolic and thrombotic events)

10

8%

Allergy (hypersensitivity)

8

7%

Pneumonia

8

7%

Sepsis

7

6%

Bleeding

5

4%

Allergic reactions depend on history: 32% in patients who had reacted to asparaginase before, 10% in relapsed patients who had not, and 3% in first-line patients. In one study, 19% of patients developed antibodies to the Oncaspar 3750 IU injection, and these correlated with allergic reactions.

Serious side effects

Serious effects are uncommon, but each needs quick action.

  • Anaphylaxis and serious allergy: Including swelling, low blood pressure, wheezing, and rash. The risk is higher with a known allergy to E. coli-derived asparaginase.

  • Clots: Including sagittal sinus thrombosis in the brain.

  • Pancreatitis: Hemorrhagic or necrotizing cases with fatal outcomes have been reported.

  • Glucose intolerance: In some cases it does not reverse.

  • Bleeding: longer clotting times and low fibrinogen can occur.

  • Liver injury: Including veno-occlusive disease (VOD), which can be life-threatening. This warning was strengthened in March 2024.

  • Reported after approval: osteonecrosis, high ammonia, higher cholesterol, and pancreatic cysts.

Critical Safety Warning

Call your local emergency number now for:

  • Swelling of the lips, face,a or eyes; wheezing; severe trouble breathing or fainting (anaphylaxis).

  • Severe headache, weakness on one side, or a seizure or confusion (possible clot in a brain vein).

  • Chest pain, shortness of breath, or a swollen arm or leg (clots).

  • Severe stomach pain, or heavy bleeding that will not stop (pancreatitis or bleeding).

Call your oncology team the same day for:

  • Yellow eyes or skin, rapid weight gain, a swollen abdomen, or pain or tenderness in the upper right abdomen (liver problems,

including VOD).

  • Excessive thirst, or passing much more urine than usual (high blood sugar).

  • Unusual bleeding or bruising.

  • Fever or signs of infection.

  • Persistent nausea, vomiting, or milder stomach pain.

The boxed warning of the Oncaspar 3750 IU injection lists five contraindications: A serious allergy to the Oncaspar 3750 IU injection or an ingredient; serious clots, pancreatitis, or serious bleeding with earlier asparaginase treatment; and severe liver impairment. Because the Oncaspar 3750 IU injection is given in the hospital, your team watches for allergy during the dose and for 1 hour afterwards.

Dosage and How To Take It

The dose of the Oncaspar 3750 IU injection depends on body surface area, and doses are at least 14 days apart. A hospital team gives each dose, with allergy-prevention medicines first. The doctor decides the schedule within the chemotherapy protocol.

Group

Dose

Route and interval

Age 21 or younger

2,500 IU/m²

Intramuscular or intravenous, no more often than every 14 days

Over age 21

2,000 IU/m²

Intramuscular or intravenous, no more often than every 14 days

Problem

What to do

Infusion or allergic reaction, grade 1

Reduce the infusion rate by 50%.

Reaction, grade 2

Interrupt, treat the symptoms, then resume at half the rate.

Reaction, grade 3 or 4

Stop permanently.

Clot, uncomplicated deep vein

Hold, treat with blood thinners, and consider resuming with blood thinners continuing.

Clot, severe or life-threatening

Stop permanently and treat

Pancreatitis, grade 3 or 4

Hold for lipase or amylase above 3 times normal until stable or falling. Stop permanently if clinical pancreatitis is confirmed

Bleeding, grade 3 or 4

Hold, check clotting, replace clotting factors if needed, and resume with the next dose if bleeding is controlled.

Bilirubin above 3 and up to 10 times normal

Hold until bilirubin is 1.5 times normal or lower.

Bilirubin above 10 times normal

Stop, and do not make up for missed doses

  • Allergy prevention: paracetamol (acetaminophen), an H1 blocker such as diphenhydramine, and an H2 blocker such as famotidine, 30 to 60 minutes before each dose.

  • Observation: at least 1 hour after the dose, with resuscitation equipment available.

  • Length of treatment: set by the chemotherapy protocol. The label gives no fixed course.

  • Food and drink: This is an injection, so food timing does not apply, and the label sets no diet rules.

For pharmacy and nursing staff

  • Allergy prevention: paracetamol (acetaminophen), an H1 blocker such as diphenhydramine, and an H2 blocker such as famotidine, 30 to 60 minutes before each dose.

  • Observation: at least 1 hour after the dose, with resuscitation equipment available.

  • Length of treatment: set by the chemotherapy protocol. The label gives no fixed course.

  • Food and drink: This is an injection, so food timing does not apply, and the label sets no diet rules.

Missed Dose

  • Oncaspar 3750 IU injection is given on a protocol schedule in the hospital.
  • If you miss a visit, call your oncology team to rebook.
  • If liver tests show bilirubin above 10 times the upper limit, treatment stops and missed doses are not made up

Safety Advice

Hospital administration

Administer only in a hospital with resuscitation equipment and medicines available to manage anaphylaxis.

Previous allergy

Assess for a history of allergic reactions to E. coli-derived asparaginase.

Pregnancy

Perform a pregnancy test before treatment. Use effective non-hormonal contraception during treatment and for 3 months after the last dose.

Breastfeeding

Avoid breastfeeding during treatment and for 1 month after the last dose.

Drug interaction (steroids)

Monitor dexamethasone exposure and steroid-related complications, including osteonecrosis.

Children

Safety and effectiveness are established in children with ALL.

Diabetes

Monitor blood glucose levels due to the risk of glucose intolerance, which may not always be reversible.

Liver impairment

Avoid use in severe hepatic impairment. The effects of hepatic or renal impairment on drug pharmacokinetics are unknown.

Monitoring During Treatment

Check

Guidance

Why

Bilirubin, liver enzymes, glucose, and examination

At least weekly until recovery from the cycle

Liver, sugar, and general toxicity

Liver tests

Before each dose, and at least weekly during cycles, through 6 weeks after the last dose

Liver injury, VOD

Pancreas

Amylase or lipase if you have abdominal pain

Pancreatitis

Clotting

PT, PTT, and fibrinogen if there are bleeding signs

Bleeding or clotting problems

After each dose

Observe for 1 hour.

Anaphylaxis

Enzyme activity

Treatment may be guided by trough asparaginase activity levels.

Confirm the enzyme is active

Fact Box

Item

Detail

What it is

Conjugate of L-asparaginase from E. coli with about 69 to 82 PEG molecules (each about 5 kDa)

US solution

Phosphate-buffered saline, pH 7.3; per mL: 750 IU, dibasic sodium phosphate 5.58 mg, monobasic sodium phosphate 1.20 mg, sodium chloride 8.50 mg

Half-life

About 5.8 days after an intramuscular dose and 5.3 days after an intravenous dose

Intramuscular absorption

Peak activity of about 1 IU/mL on day 5; bioavailability of 82% after the first dose, 98% after repeat doses

Boxed warning

Can cause serious side effects such as swelling of the lip, trouble breathing or fainting (anaphylaxis), severe headache, chest pain, etc.

Kidney and liver impairment

The effect on how the drug behaves is unknown.

Drug Interactions

Tell your team about every medicine you take. 

Category

What to Do

Risk

Glucocorticoids (Dexamethasone)

Inform your healthcare team about steroid use and monitor for steroid-related complications.

Increased dexamethasone exposure and risk of osteonecrosis and other steroid-related problems.

Other IV medications

Do not administer other medicines through the same intravenous line as Oncaspar.

Risk of incompatibility or infusion-related problems.

Other medicines

Tell your healthcare team about all prescription medicines, over-the-counter drugs, and supplements you take.

Potential drug interactions and increased risk of side effects.

FAQs

Oncaspar 3750 IU injection is used with other cancer medicines to treat acute lymphoblastic leukemia (ALL) in children and adults. It can be part of first-line treatment or used in people who are allergic to the native form of the enzyme.

It is given as part of a combination regimen, and your oncologist sets the schedule.

References

  1. Servier Pharmaceuticals LLC. ONCASPAR (pegaspargase) injection, US prescribing information, revised 3/2024.

  2. Servier Laboratories Limited. Oncaspar 750 U/ml powder for solution for injection/infusion, UK summary of product characteristics, updated 27 September 2024.

  3. Health Sciences Authority, Singapore. Oncaspar powder for solution for injection/infusion 750 U/ml (SIN16408P).

  4. Servier. Oncaspar 750 U/ml injection/infusion solution, EU leaflet text (via ).

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Magicine PharmacopyCopyright 2026